Albumin-binding antineoplastic drug-maleimide molecular prodrug

A technology of albumin-binding and maleimide, which is applied in the direction of antineoplastic drugs, drug combinations, and pharmaceutical formulations, can solve problems such as adverse reactions, low solubility of antineoplastic drugs, and lack of tumor targeting, and achieve Prolonged residence time, increased stability, and good selectivity

Active Publication Date: 2020-09-08
SHENYANG PHARMA UNIVERSITY
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] At present, chemotherapy is still the main way to treat tumors, but most anticancer drugs are easily degraded and metabolized in the blood due to their low solubility, lack of tumor targeting and serious adverse reactions, etc., which greatly limit their clinical use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Albumin-binding antineoplastic drug-maleimide molecular prodrug
  • Albumin-binding antineoplastic drug-maleimide molecular prodrug
  • Albumin-binding antineoplastic drug-maleimide molecular prodrug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Synthesis of three different linker-linked docetaxel-maleimide prodrugs.

[0042](a) Synthesis of prodrugs linked by non-sensitive bond ester bonds (abbreviated as DM): get 405mg docetaxel (DTX), dissolve 116mg maleimide caproic acid (EMC) in dichloromethane, add 210mg Dicyclohexylcarboimide (DCC), 12mg 4-dimethylaminopyridine (DMAP), N 2 The reaction was carried out at room temperature under protection for 12 h, and the white powder compound DM was obtained by separation and purification by column chromatography.

[0043] (b) Synthesis of reduction-sensitive disulfide bond-linked prodrug (abbreviated as DSSM): firstly, the key intermediate N-(2-hydroxyethyl)maleimide (compound 4) was synthesized according to the following synthetic route. Get 30g maleic anhydride and dissolve in toluene, add furan, stir at room temperature 24h stop reaction, separate out white solid in the solution, filter and collect, wash three times with toluene, dry, obtain the maleic anhydride (c...

Embodiment 2

[0056] In Vitro Binding Experiments of Three Docetaxel-Maleimide Prodrugs to Bovine Serum Albumin and Plasma

[0057] Appropriate amounts of DM, DSSM and DSM were weighed and added to bovine serum albumin pH 7.4 phosphate buffer so that the concentrations of the prodrug and bovine serum albumin were 300 μM and 700 μM, respectively. Then the mixed solution was incubated in a constant temperature shaker at 37°C, and samples were taken into high-performance liquid phase at specific time points to investigate the binding situation.

[0058] In addition, the bovine serum albumin solution was replaced with rat plasma, and the above operation was repeated to investigate the binding of the three prodrugs to plasma albumin in vitro. And use excess maleimide caproic acid to carry out competitive binding experiments: first add excess maleimide caproic acid to the plasma and incubate for 1 hour, then add each prodrug, take a point into the liquid phase, and investigate the The binding st...

Embodiment 3

[0061] In vitro release experiments of three albumin-prodrug complexes under different redox conditions

[0062] Using the conditions of the above-mentioned binding experiment, the three prodrugs were incubated with bovine serum albumin solution for 2 hours, and no free prodrug was found in the sample injection, that is, the binding was complete. The solution was then lyophilized to obtain three albumin-prodrug complexes (BSA-DM, BSA-DSSM and BSA-DSM). Then use pH 7.4 phosphate buffer containing 30% ethanol as the release medium to investigate the in vitro release of three albumin-prodrug complexes: 500 mg) was added to 1 mL of pH 7.4 phosphate buffer solution, transferred to a dialysis bag, placed in 30 mL of release medium, and sampled at the set time points at 37°C, and released by high performance liquid chromatography concentration of docetaxel. A certain concentration of hydrogen peroxide (H 2 o 2 ) or dithiothreitol (DTT), respectively, to investigate the release of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present application relates to a series of redox-sensitive albumin-bound prodrugs specifically responsive to tumor tissue, and in particular, to three small-molecule docetaxel-maleimide prodrugs. A maleimide ring in the prodrug structure is used as a target for binding a free thiol group at position 34 of a plasma albumin in the body, such that the drug rapidly and specifically binds to the albumin after intravenous injection into the body and forms an albumin-drug complex, thereby enhancing drug stability and significantly prolonging the circulation time of the drug in the body. Furthermore, the EPR effect is leveraged to achieve drug accumulation in tumor tissue.

Description

technical field [0001] The invention belongs to the field of prodrug design of pharmaceutical preparations, and relates to a redox-sensitive prodrug designed and synthesized to specifically respond to tumor tissue with endogenous plasma albumin as a carrier, and its application in antitumor. Background technique [0002] At present, chemotherapy is still the main way to treat tumors, but most anticancer drugs are easily degraded and metabolized in the blood due to their low solubility, lack of tumor targeting, and severe adverse reactions, which greatly limit their clinical use. In order to develop an efficient and safe drug delivery system, we modify the structure of antineoplastic drugs and design prodrugs that can bind to plasma albumin in vivo. Carriers for drug delivery. Albumin is the protein with the most content in plasma, and its half-life in vivo is 19 days. At present, in the field of pharmaceutical research, albumin is widely used as a drug carrier. Many drugs w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D405/12A61K47/64A61K47/54A61K45/00A61P35/00A61K31/337
CPCA61K31/337A61K45/00C07D405/12
Inventor 孙进何仲贵魏巍
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap